<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article210</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/Duodenal_Infusion_of_Donor_Feces_for_Recurrent_Clostridium_difficile" style="display:block; margin-bottom:10px;">Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile Original</a></li>
<h2><strong>Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection".The New England Journal of Medicine. 2013. 368(5):407-415.PubMed•Full text•PDFContents<br/>
<br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcomes<br/>
8.2Secondary Outcomes<br/>
9Funding<br/>
10Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
<br/>
In patients with recurrent Clostridium difficile infection, is duodenal infusion of donor feces more effective than vancomycin therapy?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
<br/>
Duodenal infusion of donor feces (fecal microbiota transplantation) is significantly more effective for the treatment of recurrent C. difficile infection than vancomycin therapy.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
<br/>
Recurrent C. difficile infection poses a significant treatment challenge, with high failure rates for standard antibiotic therapy. Fecal microbiota transplantation (FMT) has emerged as a potential solution with promising results in case series and uncontrolled studies. This trial provides strong evidence supporting the use of FMT in patients with recurrent C. difficile infection.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<br/>
As of the knowledge cutoff for this summary, specific guidelines for fecal microbiota transplantation were not described in the source text.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
<br/>
- Multicenter, open-label, randomized, controlled trial<br/>
- N=43 patients with recurrent C. difficile infection<br/>
- Interventions:<br/>
  - Duodenal infusion of donor feces after a short course of vancomycin and bowel lavage (n=17)<br/>
  - Standard vancomycin regimen (500 mg orally four times per day for 14 days) (n=13)<br/>
  - Standard vancomycin regimen with bowel lavage (n=13)<br/>
- Duration of follow-up: 10 weeks<br/>
- Analysis: Modified intention-to-treat<br/>
- Primary outcome: Cure without relapse of C. difficile infection at 10 weeks<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
<br/>
- Age at least 18 years with a life expectancy of at least 3 months<br/>
- Relapse of C. difficile infection after at least one course of adequate antibiotic therapy<br/>
- Diarrhea and a positive stool test for C. difficile toxin<br/>
<br/>
Exclusion Criteria<br/>
<br/>
- Prolonged compromised immunity (including recent chemotherapy, HIV with low CD4 count, or high-dose corticosteroids)<br/>
- Pregnancy<br/>
- Use of antibiotics other than for C. difficile treatment at baseline<br/>
- Intensive care admission or vasopressor requirement<br/>
<br/>
Baseline Characteristics<br/>
<br/>
- Mean age, sex, comorbidities, and baseline medication use not described in the source text abstract.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
<br/>
- Patients either received an abbreviated regimen of vancomycin followed by bowel lavage and donor feces infusion through a nasoduodenal tube, or one of two control treatments consisting of either a standard vancomycin regimen alone or with bowel lavage.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcomes<br/>
<br/>
- Donor feces infusion led to cure in 13 of 16 patients (81%) after the first infusion, and an additional 2 were cured after a second infusion from a different donor for an overall 94% cure rate.<br/>
- Vancomycin alone cured 4 of 13 patients (31%).<br/>
- Vancomycin with bowel lavage cured 3 of 13 patients (23%).<br/>
- The difference between the donor feces infusion group and each vancomycin group was statistically significant (P&lt;0.001).<br/>
<br/>
Secondary Outcomes<br/>
<br/>
- Changes in fecal microbiota diversity were observed post-FMT, with an increase towards levels seen in healthy donors.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
<br/>
This study was funded by the Netherlands Organization for Health Research and Development and the Netherlands Organization for Scientific Research. <br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
<br/>
The full article can be found at NEJM.org with Supplementary Material accessible at the same source.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
